HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chronic Bronchitis

A subcategory of CHRONIC OBSTRUCTIVE PULMONARY DISEASE. The disease is characterized by hypersecretion of mucus accompanied by a chronic (more than 3 months in 2 consecutive years) productive cough. Infectious agents are a major cause of chronic bronchitis.
Also Known As:
Bronchitis, Chronic
Networked: 3771 relevant articles (241 outcomes, 625 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Pneumonia (Pneumonitis)
2. Chronic Obstructive Pulmonary Disease (COPD)
3. Asthma (Bronchial Asthma)
4. Sinusitis
5. Infections

Experts

1. Miravitlles, Marc: 16 articles (01/2020 - 02/2005)
2. Martinez, Fernando J: 14 articles (01/2020 - 01/2004)
3. Anzueto, Antonio: 14 articles (01/2019 - 06/2002)
4. Raju, S Vamsee: 12 articles (01/2022 - 02/2014)
5. Rabe, Klaus F: 12 articles (11/2018 - 10/2010)
6. Rowe, Steven M: 10 articles (01/2022 - 02/2014)
7. Sethi, Sanjay: 10 articles (11/2018 - 10/2003)
8. London, Stephanie J: 8 articles (06/2022 - 06/2006)
9. Cazzola, Mario: 8 articles (06/2022 - 10/2005)
10. Singh, Dave: 8 articles (11/2021 - 10/2016)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Chronic Bronchitis:
1. Anti-Bacterial Agents (Antibiotics)IBA
2. Amoxicillin (Wymox)FDA LinkGeneric
3. Clarithromycin (Biaxin)FDA LinkGeneric
4. Ciprofloxacin (Cipro)FDA LinkGeneric
5. Ipratropium (Ipratropium Bromide)FDA LinkGeneric
6. Levofloxacin (Levaquin)FDA Link
7. Bronchodilator Agents (Bronchodilators)IBA
8. Ampicillin (Omnipen)FDA LinkGeneric
9. Erythromycin (Erycette)FDA LinkGeneric
10. MacrolidesIBA

Therapies and Procedures

1. Therapeutics
2. Drug Therapy (Chemotherapy)
3. Nebulizers and Vaporizers (Inhaler)
4. Oral Administration
01/01/2019 - "In subjects with chronic bronchitis, protection against acute bronchitis following oral administration of a whole-cell killed nontypeable Haemophilus influenzae (NTHi) preparation was demonstrated in the mid-1980s. "
01/01/1988 - "This increase in the number of pulmonary macrophages and the stimulation of their phagocytic function might explain the protective effect afforded by the oral administration of Biostim against respiratory infections in patients with chronic bronchitis."
06/01/2012 - "Studies were either double blind (n = 22 369) or open label (n = 7635) and included patients with indications that have been approved in at least one country [acute bacterial sinusitis, acute exacerbation of chronic bronchitis, community-acquired pneumonia, uncomplicated pelvic inflammatory disease, complicated and uncomplicated skin and skin structure infections, and complicated intra-abdominal infections] (n = 27 824) and patients with other indications (n = 2180), using the recommended daily dose (400 mg) and route of administration (oral, intravenous/oral, intravenous only). "
06/01/1993 - "The aim of this placebo-controlled, double-blind, parallel-group study was to evaluate whether the stimulation of the GALT through oral administration of a polyvalent bacterial extract (BE) could lead to significant immune modifications either systemically or locally in the respiratory tract in patients suffering from chronic bronchitis. "
09/01/1999 - "In one patient with chronic bronchitis, the maximum sputum concentrations 2-4 h after oral administration of 150 mg of gatifloxacin on days 1 and 6 were 0.88 and 1.45 &mgr;g/ml, respectively, and in serum the values were 0.84 and 1.24 &mgr;g/ml, respectively. "
5. Radiotherapy